New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
05:38 EDTSZYMSolazyme downgraded to Neutral from Buy at Goldman
Goldman downgraded Solazyme citing valuation and limited upside potential. The firm keeps a $13.50 price target for shares.
News For SZYM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
09:56 EDTSZYMSolazyme mentioned cautiously by TheStreetSweeper
Subscribe for More Information
October 14, 2014
17:06 EDTSZYMBraemar Energy Ventures reports 4.99% passive stake in Solazyme

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use